Riskpilot← Back to searchSign inGet full accessGLYCOZYM ApS
APSActiveCVR 25046684Pakhusvej 10, 13. tvEngineering activities and related technical consultancy · NACE 7112Est. 1999— employees
Revenue 2024
DKK 64K
-29% vs 2023
EBITDA margin
78.1%
-34% vs 2023
Equity ratio
77.5%
Financial strength
Net profit 2024
DKK -232
+96% vs 2023
| Revenue | DKK 64K | -29% |
| EBITDA | DKK 50K | -34% |
| Net profit | DKK -232 | +96% |
| Total assets | DKK 2,3M | -3% |
| Equity | DKK 1,8M | +0% |
| Employees | — | — |
Legal name
GLYCOZYM ApS
CVR number
25046684
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
15. november 1999
Share capital
DKK 200.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er: Biomedicinske aktiviteter, investeringer samt anden i forbindelse hermed stående virksomhed.
Address
Pakhusvej 10, 13. tv
Phone
+4520145537
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 79 | 163 | 71 | 58 | 0 | 1.005 | -46 | 82 | -20 | 0 | 0 | 91 | 64 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 99 | 43 | 26 | 5 | -53 | 959 | -62 | 65 | -34 | -15 | -14 | 76 | 50 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 99 | 43 | 26 | 5 | -53 | 959 | -62 | 65 | -34 | -15 | -14 | 76 | 50 |
| Net financials | -25 | -8 | -7 | -27 | 0 | 0 | -8 | -67 | -11 | 330 | 24 | -79 | -50 |
| Profit before tax | 74 | 35 | 19 | -21 | -53 | 959 | -70 | -2 | -45 | 315 | 10 | -3 | -0 |
| Tax | -0 | 1 | 5 | -0 | 11 | 135 | -0 | 21 | -8 | 19 | 3 | 3 | -0 |
| Net profit | 74 | 34 | 14 | -21 | -64 | 824 | -70 | -23 | -37 | 295 | 7 | -6 | -0 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.458 | 1.435 | 1.341 | 1.447 | 2.204 | 2.271 | 2.332 | 2.289 | 2.289 | 2.495 | 2.488 | 2.381 | 2.304 |
| Equity | 983 | 1.031 | 1.059 | 1.051 | 1.634 | 1.620 | 1.550 | 1.527 | 1.491 | 1.786 | 1.793 | 1.787 | 1.787 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 475 | 404 | 282 | 396 | 393 | 651 | 782 | 761 | 798 | 709 | 695 | 594 | 518 |
| Total debt | 475 | 404 | 282 | 396 | 393 | 651 | 782 | 761 | 798 | 709 | 695 | 594 | 518 |
EBITDA margin
78.1%
This company
15.8%
Market median
+394% vs market
20122024
Equity ratio
77.5%
This company
38.2%
Market median
+103% vs market
20122024
Return on equity
-0.0%
This company
18.4%
Market median
-100% vs market
20122024
Net profit margin
-0.4%
This company
8.1%
Market median
-105% vs market
20122024
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20122024
Debt / equity
0.29×
This company
0.62×
Market median
+53% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PA Management | Management | 1999 | — | — |
HS Audit | Audit | 2000 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 66.7% | 66.7% | 1999 | |
| Individual | 25.0% | 25.0% | 1999 | |
| Individual | 25.0% | 25.0% | 1999 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
GLYCOZYM ApS 
Kaplock ApSBoard members of GLYCOZYM ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Andreas Stakemann | Management | 0 companies |
| Henrik Søeborg | Audit | 0 companies |